Logo image of MLYS

MINERALYS THERAPEUTICS INC (MLYS) Stock Fundamental Analysis

USA - NASDAQ:MLYS - US6031701013 - Common Stock

43.89 USD
-0.37 (-0.84%)
Last: 11/18/2025, 12:23:41 PM
Fundamental Rating

3

MLYS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. While MLYS has a great health rating, there are worries on its profitability. MLYS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MLYS had negative earnings in the past year.
MLYS had a negative operating cash flow in the past year.
In the past 5 years MLYS always reported negative net income.
In the past 5 years MLYS always reported negative operating cash flow.
MLYS Yearly Net Income VS EBIT VS OCF VS FCFMLYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

MLYS has a Return On Assets of -56.82%. This is comparable to the rest of the industry: MLYS outperforms 44.65% of its industry peers.
With a decent Return On Equity value of -60.84%, MLYS is doing good in the industry, outperforming 60.98% of the companies in the same industry.
Industry RankSector Rank
ROA -56.82%
ROE -60.84%
ROIC N/A
ROA(3y)-46.99%
ROA(5y)-109.19%
ROE(3y)-50.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MLYS Yearly ROA, ROE, ROICMLYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MLYS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MLYS Yearly Profit, Operating, Gross MarginsMLYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, MLYS has more shares outstanding
There is no outstanding debt for MLYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MLYS Yearly Shares OutstandingMLYS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
MLYS Yearly Total Debt VS Total AssetsMLYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

MLYS has an Altman-Z score of 87.97. This indicates that MLYS is financially healthy and has little risk of bankruptcy at the moment.
MLYS has a better Altman-Z score (87.97) than 98.69% of its industry peers.
MLYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 87.97
ROIC/WACCN/A
WACCN/A
MLYS Yearly LT Debt VS Equity VS FCFMLYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 15.12 indicates that MLYS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 15.12, MLYS belongs to the top of the industry, outperforming 91.18% of the companies in the same industry.
MLYS has a Quick Ratio of 15.12. This indicates that MLYS is financially healthy and has no problem in meeting its short term obligations.
MLYS has a Quick ratio of 15.12. This is amongst the best in the industry. MLYS outperforms 91.18% of its industry peers.
Industry RankSector Rank
Current Ratio 15.12
Quick Ratio 15.12
MLYS Yearly Current Assets VS Current LiabilitesMLYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

MLYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.79%, which is quite good.
EPS 1Y (TTM)9.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MLYS will show a very strong growth in Earnings Per Share. The EPS will grow by 22.84% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.62%
EPS Next 2Y12.94%
EPS Next 3Y5.26%
EPS Next 5Y22.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MLYS Yearly Revenue VS EstimatesMLYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
MLYS Yearly EPS VS EstimatesMLYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MLYS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLYS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLYS Price Earnings VS Forward Price EarningsMLYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLYS Per share dataMLYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.94%
EPS Next 3Y5.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MLYS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MINERALYS THERAPEUTICS INC

NASDAQ:MLYS (11/18/2025, 12:23:41 PM)

43.89

-0.37 (-0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)02-10 2026-02-10/amc
Inst Owners91.76%
Inst Owner Change21.36%
Ins Owners1.87%
Ins Owner Change-9.56%
Market Cap3.32B
Revenue(TTM)N/A
Net Income(TTM)-190.77M
Analysts84
Price Target46.79 (6.61%)
Short Float %9.75%
Short Ratio4.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.63%
Min EPS beat(2)10.13%
Max EPS beat(2)21.13%
EPS beat(4)3
Avg EPS beat(4)2.32%
Min EPS beat(4)-32.79%
Max EPS beat(4)21.13%
EPS beat(8)5
Avg EPS beat(8)5.53%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)20.69%
EPS NQ rev (1m)3.56%
EPS NQ rev (3m)11.85%
EPS NY rev (1m)1.87%
EPS NY rev (3m)6.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10.57
P/tB 10.57
EV/EBITDA N/A
EPS(TTM)-2.95
EYN/A
EPS(NY)-2.64
Fwd EYN/A
FCF(TTM)-2.56
FCFYN/A
OCF(TTM)-2.55
OCFYN/A
SpS0
BVpS4.15
TBVpS4.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.82%
ROE -60.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.99%
ROA(5y)-109.19%
ROE(3y)-50.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 66.67%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.12
Quick Ratio 15.12
Altman-Z 87.97
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.98%
EPS Next Y24.62%
EPS Next 2Y12.94%
EPS Next 3Y5.26%
EPS Next 5Y22.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-51.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.9%
EBIT Next 3Y-0.64%
EBIT Next 5Y29.25%
FCF growth 1Y-105.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.89%
OCF growth 3YN/A
OCF growth 5YN/A

MINERALYS THERAPEUTICS INC / MLYS FAQ

What is the fundamental rating for MLYS stock?

ChartMill assigns a fundamental rating of 3 / 10 to MLYS.


Can you provide the valuation status for MINERALYS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to MINERALYS THERAPEUTICS INC (MLYS). This can be considered as Overvalued.


Can you provide the profitability details for MINERALYS THERAPEUTICS INC?

MINERALYS THERAPEUTICS INC (MLYS) has a profitability rating of 1 / 10.


What is the earnings growth outlook for MINERALYS THERAPEUTICS INC?

The Earnings per Share (EPS) of MINERALYS THERAPEUTICS INC (MLYS) is expected to grow by 24.62% in the next year.